Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRYSTAL-4: Adagrasib + Pembrolizumab + Chemotherapy in 1L KRAS G12C-Mutated NSCLC
NCT06875310Phase 3Recruiting
- Sponsor
- Mirati Therapeutics
- Start
- Apr 2025
- Primary completion
- Sep 2029
- Modality
- Small Molecules
- Countries
- 35
01
Overview
A Phase 3 trial of adagrasib in non-small cell lung cancer (NSCLC), sponsored by Mirati Therapeutics. Started Apr 2025; status: recruiting.
02
Drugs
adagrasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06875310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06875310.